No profile data available.
PepGen Inc. (PEPG) is a healthcare company in the brain and nerve treatment drugs industry, based in Boston, United States, with about 57 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$89.66 million. Its market capitalization was $181.46 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.
PepGen reported $0 in revenue for fiscal year 2025.
$181.46 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Entrada Therapeutics, Inc. (TRDA), Alpha Cognition Inc. (ACOG), Inhibikase Therapeutics, Inc. (IKT), Acumen Pharmaceuticals, Inc. (ABOS).